#1 Ranked Children’s Hospital by U.S. News & World Report
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
There are many ways you can help children and their families get the care they need.
For more than a century, orthopedic surgeons and investigators at Boston Children’s Hospital have played a vital role in the field of musculoskeletal research, pioneering major treatment approaches for many conditions.
Bone and Soft Tissue Tumor Research
The main objective of our research program is to improve the understanding of bone and soft tissue cancers and develop new ways to treat children with these conditions. We are actively pursuing our own research initiatives, as well as participating in those directed by the Boston Children’s Oncology Group, an international research collaboration.
Translational research. Children’s is a world leader in opening new avenues of "translational research"—bringing laboratory advances to the bedside and doctor's office as quickly as possible. All of our senior medical staff members of the Bone and Soft Tissue Tumor Program participate in clinical research activities. Our program director, Carlos Rodriguez-Galindo, MD, is also the co-director of our new Clinical and Translational Investigation Program, which aims to dramatically improve translational research in pediatric hematology and oncology.
Boston Children’s Oncology Group
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center is the New England Phase I Center of the Children's Oncology Group. If your child has a progressive or recurrent bone or soft tissue tumor, he may be eligible for a number of experimental therapies available through these groups, or through one of our independent clinical investigators.
The Boston Children's Oncology Group is a consortium of cancer treatment centers across the United States, Canada, and other countries, that conduct studies of Ewing’s sarcoma, osteosarcoma, rhabdomyosarcoma and other soft tissue sarcomas. Our participation in the Children’s Oncology Group gives children with bone and soft tissue tumors unparalleled access to the newest clinical trials.
In addition to a wide variety of clinical trials, Boston Children’s also conducts extensive laboratory research to identify new treatments and improve therapies for bone and soft tissue tumors.
We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”